New pill plus immunotherapy takes on tough melanoma

NCT ID NCT06624644

Recruiting now Disease control Sponsor: Linnaeus Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, LNS8801, taken as a daily pill, either alone or with the immunotherapy pembrolizumab, in people with advanced melanoma that has not responded to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plus pembrolizumab, or standard treatments chosen by their doctor. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LNS8801 (a tablet that targets a protein called GPER) and pembrolizumab (an immunotherapy drug)
What this could lead to: If it works, this could offer a new treatment option for people with advanced melanoma that has stopped responding to standard therapies.
What could go wrong: This is an early-to-mid stage trial with only 135 participants, so results may not apply to everyone. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS MELANOMA MELANOMA (SKIN CANCER) MELANOMA STAGE IIIB-IV UNRESECTABLE MELANOMA

Contacts and locations

Show contact details

Locations

Dana Farber
RECRUITING

Boston, Massachusetts, 02215, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 87535, United States
Stanford
RECRUITING

Stanford, California, 94305, United States
UCSF
RECRUITING

San Francisco, California, 94143, United States
UPenn
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
USC Newport Beach
RECRUITING

Newport Beach, California, 92663, United States
University of Colorado
RECRUITING

Denver, Colorado, 80204, United States

Contact Email: •••••@•••••
University of Colorado Anschutz
RECRUITING

Aurora, Colorado, 80045, United States
University of New Mexico
RECRUITING

Albuquerque, New Mexico, 87106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.